Just want to recap the future of BDSI since there is not so much discussion going on, but a bunch of bashers.

From Spry@Google board >>

This fall is not permanent. I've been frustrated as well, but take a
look:

Future catalysts From Mike Havrilla:


1.) BDSI will begin receiving double-digit royalties from Meda AB on
net sales of Onsolis following U.S. commercial launch on 10/12/09


2.) Preliminary Phase 2 dental pain BEMA Buprenorphine study results
are expected in December 2009


3.) A study evaluating Onsolis for non-cancer breakthrough pain is
expected to start during 1Q10 and will be funded by Meda AB


4.) A Phase 3 acute pain study for BEMA Buprenorphine is expected to
start during 2Q10


5.) The E.U. approval of Onsolis (Breakyl) is expected during 1H10 and
a New Drug Submission for BEMA Fentanyl was made to Health Canada in
early October 2009 by partner Meda Valeant Pharma Canada Inc.


(BDSI has retained the rights to BEMA Fentanyl in South Korea and
Taiwan)


6.) A BEMA Buprenorphine partnership is expected during 2H10 with a
goal of submitting a NDA for FDA approval during 1H11


7.) Expected completion of Phase 1 Bioral Amphotericin B trial by year-
end with start of Phase 2 trial expected during 1H10 and Phase 3
development expected in 2011


BDSI anticipates that peak sales have the potential to exceed $200
million for Onsolis with additional indications possible for non-
cancer breakthrough pain, which will be evaluated in a clinical trial
slated to begin early next year. BDSI is also developing BEMA
Buprenorphine, BEMA 5HT-3 Antagonist (nausea / vomiting), BEMA Triptan
(migraine headaches), and Bioral Amphotericin B (fungal infections).


Patience is key here. Don't check the stock price daily. It may
continue to go down until next month.

Spry